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Introduction: Osteoporosis and bone fractures are common in chronic obstructive pulmon-
ary disease (COPD) and contribute significantly to morbidity and mortality. Current national
guidance on COPD management recommends addressing bone health in patients, however,
does not detail how. This consensus outlines key elements of a structured approach to
managing bone health and fracture risk in patients with COPD.
Methods: A systematic approach incorporating multifaceted methodologies included
detailed patient and healthcare professional (HCP) surveys followed by a roundtable meeting
to reach a consensus on what a pathway would look like.
Results: The surveys revealed that fracture risk was not always assessed despite being recog-
nised as an important aspect of COPD management by HCPs. The majority of the patients also
stated they would be receptive to discussing treatment options if found to be at risk of
osteoporotic fractures. Limited time and resource allocation were identified as barriers to
addressing bone health during consultations. The consensus from the roundtable meeting was
that a proactive systematic approach to assessing bone health should be adopted. This should
involve using fracture risk assessment tools to identify individuals at risk, investigating second-
ary causes of osteoporosis if a diagnosis is made and reinforcing non-pharmacological and
preventative measures such as smoking cessation, keeping active and pharmacological manage-
ment of osteoporosis and medicines management of corticosteroid use. Practically, prioritising
patients with important additional risk factors, such as previous fragility fractures, older age and
long-term oral corticosteroid use for an assessment, was felt required.
Conclusion: There is a need for integrating fracture risk assessment into the COPD path-
way. Developing a systematic and holistic approach to addressing bone health is key to
achieving this. In tandem, opportunities to disseminate the information and educational
resources are also required.
Keywords: COPD, fracture risk, osteoporosis, bone health
Key Points
● Fracture risk in patients with COPD is not always comprehensively addressed,
despite its importance being highlighted by healthcare professionals.
● A proactive systematic approach to addressing bone health in people with COPD
should be adopted where possible. Time and resource are major barriers.
● Whilst assessment for osteoporosis should be carried out for all patients with
COPD, this may not be feasible. Prioritizing a risk assessment in patients with
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important additional risk factors such as previous
fragility fractures, older age and on long-term oral
corticosteroids may be the pragmatic approach.
● Fracture risk assessment should be carried out in all
newly diagnosed patients with COPD within 6–12
months of diagnosis.
● Annual COPD reviews provide a suitable setting in
which bone health can be addressed for patients with
established COPD, provided healthcare professionals
receive adequate training and resources.
● Fracture risk prediction tools, such as FRAX® and
QFracture®, should be used to identify high-risk
patients and aid targeted use of DEXA scans.
● Other secondary causes of osteoporosis are common
and should be investigated accordingly where osteo-
porosis is detected in patients with COPD.
● Management of osteoporosis in COPD should focus
on conservative measures such as smoking cessation
and exercise in addition to pharmacological therapy.
● Patient information on bone health is required.
Background
Osteoporotic fractures are common worldwide,1–3 have
a debilitating impact on patients and in the UK confer
a significant economic burden on the National Health
Service (NHS).3,4 More than half of adult women and one
in five men are believed to sustain one or more fragility
fractures in their lifetime.5 It was estimated that in 2010
these fractures cost the NHS £4.4 billion and contributed to
increased pain, disability and mortality for patients.3
Chronic obstructive pulmonary disease (COPD), primarily
a respiratory condition but with known co-morbidities and
extra-pulmonary manifestations, is linked to an increased
risk of osteoporosis and fractures.6–10 When bone densito-
metry has been systematically performed, up to a third of
patients with COPD have evidence of osteoporosis.7
Furthermore, the risk of falls, which is an important deter-
minate of fragility fractures,11 is also increased in patients
with COPD likely owing to a range of factors including
impaired balance,12 poor muscle strength13 and cognitive
deficits.14 As a result, people with COPD experience
a greater risk of hip fracture than their matched counterparts
without COPD.15 In one cohort, nearly half of patients with
a surgical hip fracture had a diagnosis of COPD amongst
their co-morbidities.16 The impact of fragility fractures
specifically in people with COPD is of particular impor-
tance, owing to its contribution to morbidity and
mortality.17,18 Osteoporosis-related vertebral fractures can
limit lung function through associated kyphosis. In addi-
tion, rib fractures that are known to cause chest pain may
lead to hypoventilation and reduced sputum clearance, with
the possibility of worsening exacerbations.18 Given at least
1.2 million people in the UK are currently living with
COPD,19 fracture risk in the context of COPD represents
a significant and common clinical problem, yet the clinical
pathway for this is far from clear.
National institute of clinical excellence (NICE) guide-
lines for osteoporosis recommend that COPD is a secondary
cause of osteoporosis and therefore that a systematic assess-
ment of fracture risk is required.20 This systematic assess-
ment is not incorporated into either the NICE COPD
guidelines 2010 or 201821,22 but they do refer to considera-
tion of fracture risk in people with repeated oral corticoster-
oids. The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2019 strategy on management of COPD
recommends active assessment and appropriate treatment of
osteoporosis but it does not describe how and when this
assessment should be carried out.23
Whilst the endeavour for clinicians should be to recog-
nise bone health within COPD care, the lack of informa-
tion detailing a systematic approach may make this
challenging. There is a need for integrating osteoporosis
assessment into the COPD pathway and managing both
falls and fracture risk for people with COPD. Meanwhile,
any change in the COPD pathway to accommodate this
needs to be feasible as well as be acceptable to healthcare
professionals (HCPs), carers responsible for people with
COPD, and the patients themselves.
Aims and Objectives
To reach consensus on practically incorporating the assess-
ment and management of bone health and fracture risk in
patients with COPD, through a series of coordinated
mixed method approaches, including:
● Seeking opinion of people living with COPD of bone
health with respect to knowledge, experience and views.
● Seeking opinion from HCPs to determine knowledge
of, experiences and clinical practices associated with
managing bone health and fracture risks in COPD
patients.
● Collating surveys with available published evidence
to form the basis of a roundtable meeting with key
stakeholders including many multidisciplinary HCPs
across respiratory, bone disease specialities in pri-
mary and secondary care to reach the consensus.
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In addition, the aim was to discuss how the awareness of
bone health in people with COPD could be raised with
both patients and healthcare professionals and how the
training could be delivered to healthcare professionals
who manage patients with COPD.
Method
Ethical Approval
The survey protocol and plan were reviewed by the
University of Nottingham research ethics department and
the outcome was that this did not need a full ethics com-
mittee review or approval as the participants were provid-
ing their expert knowledge and experience to inform about
the topic rather than being the subject of the topic in
question (Ethics reference number: 81–1807).
Survey for People with COPD
The survey was developed by the research team and
refined and piloted with the help of two members of
different regional support groups for people with respira-
tory disease: “Breathe Easy”. Both members were
trained in patient and public engagement; one a patient
advocate and the other a person with a chronic lung
condition. The aims of the survey and confirmation of
anonymity were introduced at the start of the survey.
This allowed implied consent. The survey (see online
supplement 1) comprised of two sections: 1) partici-
pants characteristics including diagnosis and experiences
of fractures and 2) knowledge and experience, including
the link between COPD and bone thinning and of any
care/treatment in relation to bone thinning. There were
several questions with a choice of responses as well as
opportunity for free text throughout the survey.
A link to the “live” patient survey (via onlinesurveys.ac.uk)
was emailed to “Breathe Easy” groups across the East
Midlands alongside hard copies of the surveys posted for
distribution at their monthly meetings. Pre-paid envelopes
were provided for completed questionnaires to be returned.
The NIHR Nottingham Biomedical Research Centre (BRC)
Respiratory theme posted the link on their website, Facebook
and Twitter accounts, and the research team promoted via their
personal work-related Twitter accounts. This reached a wider
geographical area than East-Midlands. Online responses were
downloaded directly from onlinesurveys.ac.uk into STATA
and paper copies were manually entered into STATA by one
of the researchers. Quality checks of data inputted were
performed.
Survey for Healthcare Professionals
The survey for HCPs was also developed by the research
team and piloted by four independent HCPs for content,
ease of use, timing and accuracy and then refined prior to
launch on onlinesurveys.ac.uk. The survey introduction
outlined the aims of the project along with the online
survey and confirmed that the survey was anonymous.
Questions were themed across four sections:
1. Participants’ characteristics;
2. Knowledge of the link between COPD and bone
thinning;
3. Beliefs and attitudes towards their role in its treat-
ment; and
4. Practice in treating/discussing the link (see online
supplement 2)
Over 160 HCPs were identified as potential recipients through
the teams’ professional networks; all had experience in mana-
ging patients with COPD or lung disease, across a number of
healthcare roles in the UK. In many instances, respiratory
disease was not the core part of their job role. The identified
HCPs were sent an introductory email containing a link to the
survey and politely asked to forward the questionnaire link
onto others who might be eligible to complete it. The survey
was also promoted on social media (Facebook and Twitter)
through Primary Care Respiratory Society UK (PCRS UK),
East Midlands Thoracic Society (EMTS), National Institute
for Health Research (NIHR), Nottingham BRC Respiratory
theme, and the research team’s work-related accounts.
Information regarding the survey was also posted on the
PCRS UK website.
Both surveys were only available in English and data
collection took place over a four-week period during July and
August 2018 in parallel. Participants were asked to contact the
research team if they had any concerns, wanted to be involved
in further work orwished to receive a summary of the findings.
Data Analysis
Quantitative and qualitative content analysis was used to
collate written comments by patients and HCPs in their
respective survey as it enabled researchers to establish
a set of categories (in this instance, themes derived from
the responses to questions) and then count up the number of
instances that fall into this category.24 One researcher read
all comments for each question and preliminary themes were
Dovepress Gupta et al
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derived from grouping similar responses. The number of
comments under each theme were then calculated.
Roundtable Session with Key
Stakeholders to Gather Consensus on
Managing Bone Health and Fracture Risk
in Patients with COPD
Multidisciplinary HCPs involved in either COPD care or
osteoporosis were invited to participate in a structured
roundtable discussion on this topic in September 2018.
Invites were made to give balanced representation across
primary and secondary care and across multidisciplinary
roles (nursing, physician, physiotherapy and pharmacy).
The invitees were from different regions of the country
including London, East Midlands, West Midlands and
Somerset. Some members in the consensus meeting also
had subspecialist interests in areas relevant to the subject
matter; one physician was a geriatric consultant represent-
ing the Nottingham Osteoporosis Support Group and
another was a GP present on behalf of PCRS. The meeting
room hire and light refreshments were supported through
funding by the British Lung Foundation (BLF). A summary
of the results from both surveys was disseminated out to all
delegates before the meeting. More in-depth results and
further questions were sent out to three HCPs who could
not attend in person but were able to provide comprehensive
feedback, which was then incorporated into the roundtable
discussion by two members of the research team. At the
meeting, a detailed background of published literature was
presented followed6–8,15,20,22,23,25,26–34 by an in-depth pre-
sentation of the surveys (full raw datasets were available for
review too). The group was then divided into two with
a facilitator each to carry out a structured discussion process
with regards to a pathway addressing bone health. Key
questions discussed within the groups included:
● “Should we be offering assessment of fracture risk to
all patients with COPD?”
● “What should the patient pathway look like?”
● “Are there any other considerations of bone health?”
Discussions were audio recorded for researcher reference,
but no direct quotes are used in the write-up and anonymity
was maintained. The content of the structured discussions
was analysed for common themes relating to the key ques-
tions. Given that this was a consensus report on key elements
of a structured approach to managing bone health and frac-
ture risk in patients with COPD rather than development of
national guidelines, the decision outcomes were not formally
graded according to literature evidence but were
a representation of the invitees’ recommendations, focusing
on pragmatic and practical opportunities to addressing bone
health.
Results
Patient Survey
Demographics
Of the 51 respondents in the patient survey, 41 had
a diagnosis of COPD (or classed themselves as having
chronic bronchitis or emphysema) and were included in
the analysis. The other 10 respondents who had bronch-
iectasis, asthma, pulmonary fibrosis, sleep apnea or raised
hemidiaphragm were excluded from the formal analysis
but their responses were reviewed for any salient points
that might need to be discussed later. More than half [n=24
(59%)] of the patients with COPD were female.
The vast majority (n=35) of the patients were ex-
smokers with a further 3 patients never smoked and 3
current smokers. Most were over the age of 60 years;
51% 60 to 74 years and 46% 75+ years. Five (12%) of
the patients had a diagnosis of osteoporosis and 11 (27%)
were on bone protection treatment (Table 1).
Knowledge
Patients were asked to give their response to their understand-
ing of osteoporosis in COPD and their experiences. More than
half of the cohort replied “Don’t know” when asked about
their understanding of osteoporosis in COPD. The majority of
patients (58%) stated they had not previously been assessed
for osteoporosis or its risk factors by an HCP. When asked
how receptive they would be to discuss treatment options if at
risk of osteoporosis, 73% of patients replied they would be
either very or moderately receptive. Furthermore, if provided
with a leaflet on osteoporosis, respondents would be particu-
larly interested in reading about the causes, diagnosis and the
treatment involved, especially what lifestyle changes they
could make to improve their bone health.
Healthcare Professional Survey
Demographics
There were 147 responses to the HCP survey however two
participants were excluded from the analysis as they
reported not seeing/assessing any patients with COPD.
Of the included 145, 79% were female and the majority
were from the Midlands (70%) with 2% from overseas (all
Gupta et al Dovepress
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Europe). The breakdown of job roles was as follows: 41%
nurse with experience in managing COPD, 28% hospital
doctor, 12% GP, and 19% other HCPs. The majority of the
HCPs (85%) had worked in the NHS for more than 10
years. The proportion of patients who had COPD from
their full case load were <25%: 25%; 25–49%: 23%;
50–74%: 22% and ≥75%: 30%.
Knowledge
When asked what proportion of patients with COPD were
at risk of osteoporosis, the responses were varied: <20%
10%; 21–40% 23%; 41–60% 34% and 61–75% 12%.
More than half of HCPs (61%) had heard of the fracture
risk assessment scores, Frax® and QFracture®. On a scale
of 1–10 of the importance of bone health (1 being not
important at all and 10 being extremely important), 74% of
the respondents scored it 7 or greater. Meanwhile, an
overwhelming majority (95%) thought bone health was
under-addressed. As for where discussions around bone
health should occur, the annual COPD assessment (88%),
hospital out-patient appointment (77%), follow-up after an
exacerbation (61%) were the most popular answers (parti-
cipants could select more than one answer). How often the
various aspects of COPD care were commonly advised
upon is summarised in Figure 1.
When bone health was discussed in a COPD consulta-
tion, nearly three quarters of HCPs discussed it broadly
and a few referred for a dual-energy X-ray absorptiometry
(DEXA) bone densitometry or assessed fracture risk. Only
6% did a formal fracture risk score (such as Frax®) routi-
nely. Less than 50% either “routinely” or “occasionally”
referred patients for a bone DEXA scan, the majority
(81%) thought patients were at least somewhat receptive
to discussing bone health.
HCPs felt the top managements or therapies offered to
COPD patients with an increased fracture risk were “brief
advice” (51%), oral calcium and vitamin D (58%), diet
advice (57%), increase physical activity (54%), and
a DEXA bone scan (52%) (participants could select more
than one answer). Half (48%) of respondents offered
bisphosphonates to COPD patients viewed to be at an
increased fracture risk.
From the free text responses, the two biggest barriers for
HCPs in providing advice on fracture risk/risk of osteoporo-
sis were time (44% of free text response raised this as an
issue) and knowledge/guidance of how to deal with the issues
(42% of responses). Other issues to a lesser extent included
access to DEXA and information overload for patient.
Half of HCPs (49%) highlighted the importance of
more training to facilitate discussions with patients to
assess bone health, fracture risk and offer more general
advice in this area. On top of this, nearly half (42%) of
HCPs said in this instance a patient information leaflet
would be valuable. The other request was providing clear
local or national guidance.
Roundtable Consensus Meeting
Discussion of Patient and HCP Surveys
There were 13 professionals (including two methodolo-
gists) at the meeting and a further three (one GP with
a specialist interest in respiratory medicine, one consultant
integrated respiratory physician and one respiratory phar-
macy consultant) were unable to attend but offered com-
ments prior to the meeting on the survey results and
questions to be posed.
Overwhelmingly, the view of the attendees was that the
profile of bone health in patients with COPD needs to be
Table 1 Survey Responses from Patients with COPD
N= 41 %
Who Do You See for Your Lung Condition?
(Patients Can Select More Than One Option)
GP 29 71
Hospital doctor 12 29
COPD nurse 25 61
Respiratory nurse 12 29
Have You Ever Completed Pulmonary Rehabilitation?a
Yes 34 83
No 7 17
Since Being Diagnosed, Have You Ever Broken a Bone?
Yes 5 12
No 36 88
Have You Got a Diagnosis of Osteoporosis?
Yes 5 12
No 26 63
Do not know 10 25
Are You on Tablets for Osteoporosis?
Yes 11 27
No 28 68
Do not know 2 5
Do You Take Tablets Containing Vitamin D?
Yes 14 34
No 23 56
Do not know 4 10
Notes: aSix- to eight-week-long exercise-based programme consisting of strength
and endurance training, nutritional counselling, self-management strategies and
breathing technique advice, prescribed to patients with cardio-respiratory disease.
Dovepress Gupta et al
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raised. The striking mismatch in the survey by HCPs was
highlighted; that most respondents felt assessment of bone
health during consultations is “important” or “very impor-
tant” but also that the subject is under-addressed. Reasons
for such a discrepancy were further explored; it was felt
that the current challenges of insufficient allocated time
with patients, lack of resources particularly availability of
DEXA scanning and educational needs for clinicians and
awareness for patients prevented consideration of a robust
systematic approach.
Ongoing discussion followed that the lack of a single
patient record traversing primary and secondary care in the
NHS may lead to a risk of omission or duplication.
Furthermore, many felt there was insufficient time cur-
rently in a COPD review held in the primary care setting
for core elements to be addressed; already having to prior-
itise between inhaler technique checks, health promotion
advice, addressing patients’ ideas and concerns, reviewing
lung function and assessing for other important co-
morbidities, such as cardiovascular disease. Patients self-
completing some questions prior to the consultation and
software extracting and populating the fracture risk ques-
tions where possible were suggested solutions. These
questions could include the clinical risk factors incorpo-
rated into the fracture risk assessment tools, such as smok-
ing and alcohol status, history of previous fractures, family
history (parent) of hip fractures, comorbidities
(rheumatoid arthritis and other secondary causes of osteo-
porosis) and glucocorticoid use.
“Should We Be Offering Assessment of Fracture Risk to
All Patients with COPD?”
This question was divided up into sections according to
the nature of patients, as outlined below:
Current COPD diagnosis: There was a view that more
could be done within the current system but that it was
currently aspirational to deliver a systematic approach to
bone health to all patients with already diagnosed COPD.
However, a pro-active (eg assess early and prevent) rather
than a re-active (eg treat once fracture occurs) was agreed.
It was proposed that for people currently diagnosed with
COPD the annual review would be an ideal setting to
assess bone health. However, in such a setting if
a systematic review for osteoporosis and fracture risk has
not occurred before, the practical approach would be to
search for those at most risk (previous low impact frac-
tures, current smokers, low body mass index (BMI),
severe COPD, frequent steroid courses) and prioritise
their review. The aim would be to eventually provide
a comprehensive review for all people with COPD.
New COPD diagnosis: Following discussion, a view
held across the majority of the attendees was that bone
health should be assessed at around the time of COPD
diagnosis (during a 6–12 month period) and thereafter as
Figure 1 A bar chart showing how often topics in the management of COPD are addressed during consultations as reported by healthcare professionals.
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part of the considerations at annual COPD reviews every
3–5 years.
All COPD patients: It was suggested that settings such
as a pulmonary rehabilitation programme, review by the
community respiratory teams and secondary care outpati-
ent clinics, could offer an alternative opportunity for ascer-
taining fracture risk for patients but that these do not
systematically address the COPD population as a whole.
Cautions: Consideration was given to patients where it
may not be appropriate to undergo comprehensive inves-
tigations or treatment, such as those receiving palliative
end of life care. Furthermore, if a patient had already
sustained a fragility fracture, it was felt that they did not
need to undergo a further fracture risk score but should be
considered high risk and managed accordingly.
It was debated whether all people with COPD starting
bone protection medication should have a DEXA bone
densitometry alongside the fracture risk score with clear
information on when to repeat. One argument was that
baseline bone mineral density (BMD) measurements
would be needed if treatment response was to be moni-
tored. Furthermore, DEXA scans are relatively cheap and
easy to arrange. However, current availability of scanning,
especially if large numbers were referred may delay
obtaining results and consequently treatment.
“What Would the Patient Pathway Look Like?”
The following recommendations were made for patients
aged 50 years and over:
● Assess bone health within 6−12 months of a new
COPD diagnosis.
○ Then, regular review (at least every 3–5 years,
likely during a COPD annual review to enable
treatment to be considered and started or poten-
tially stopped)
● For patients who have an established diagnosis of
COPD, the annual review is ideal for assessing bone
health but other opportunities such as hospital COPD
out-patient appointments and pulmonary rehabilita-
tion also provide opportune times and it is every
HCP working with patients with COPD responsibility.
○ Regular review should be carried out every 3–5
years during the annual review.
● If already sustained a fragility fracture – consider the
person high risk and establish on therapy.
● A history of fragility fractures can be usually elicited
during the clinical consultation, but given the
asymptomatic nature of vertebral fractures, some
patients may remain undiagnosed. With this in
mind, review previous radiological imaging or orga-
nise appropriate vertebral X-rays if there is a clinical
suspicion (loss in height) to identify vertebral
fractures.
● For all others, to complete a fracture risk score.
● Consider a DEXA bone densitometry for those in
intermediate range or where considering pharmaco-
logical treatment.
● Consider how to tell patients of the risk.
● Consider risk in the context of other co-morbidities.
Special Considerations
● Consider all patients high risk regardless of age if
there is a previous history of fragility fractures
● Patients younger than 50 years with multiple other
risk factors (but no previous fragility fracture),
a decision on treatment decisions is based on clinical
judgement
● Patients on maintenance (7.5mg or more for more
than 3 months) or frequent (3 or more) use of sys-
temic glucocorticoids consider
○ If over 70 years old – consider high risk
○ If 50–70 years old, assess fracture risk using frac-
ture risk calculator
○ For those <50 years old, treatment decisions on
clinical judgement
The International Osteoporosis Foundation (IOF)–European
Calcified Tissue Society recommends initiating bisphospho-
nates for patients on long-term steroids above the age of
70 years or who are on high dose steroids (more than
7.5mg/day of prednisolone or equivalent).35,36
The group agreed that for those with diagnosed osteo-
porosis, other secondary causes for osteoporosis should be
addressed. Basic blood tests pertaining to secondary
causes should be considered in those with evidence of
osteoporosis (Table 2).
Table 3 highlights management options available for
patients at risk of fragility fractures. There was agreement
that this included pharmacological therapy but also
non-pharmacological options were imperative. Such
a consultation discussing treatment needs a receptive
patient and an informed clinician. Monitoring the side
effect profile of bisphosphonates was also suggested, espe-
cially gastro-oesophageal reflux disease (GORD) and
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osteonecrosis of the jaw; the former being a relatively
common side effect also usually prevalent in COPD and
the latter a serious complication of long-term
bisphosphonate use.23,37 Reasons for a referral to
a metabolic bone disease specialist are also stated in
Table 4.
In order to raise the profile of bone health, the group
felt there needs to be better health promotion for patients
and more educational opportunities for HCPs. Suggestions
discussed included whether it could be in the BLF passport
alongside other common and clinically relevant co-
morbidities, developing a comorbidities/bone health leaflet
for patients and an educational campaign for HCPs in
order to contextualise the benefits of treatment. Another
recommendation was to calculate the cost–benefits of
reducing fracture risk in patients with COPD and numbers
needed to treat to emphasise the importance of fracture
risk assessment and treatment to GPs.
Discussion
Osteoporotic fractures in the general population are extre-
mely debilitating.1–3 Within the context of COPD they
play a significant role in contributing to disease
burden.17,18 Yet, there is limited guidance on how to
address bone health within the COPD pathway. Whilst
the NICE guidelines on osteoporosis emphasize the need
for assessment of fracture risk in all patients with COPD,20
there is a lack of information on how this should be
implemented into the COPD assessments and when.
Furthermore, much of the literature assessing fracture
risk in COPD is carried out in a select population, with
little literature on a validated systematic process of asses-
sing fracture risk. This statement outlines the key elements
needed for a structured approach to addressing bone
health, developed through a series of multifaceted meth-
odologies consisting of patient and HCP surveys and
a roundtable meeting to reach a consensus on the issue.
Both surveys highlighted that bone health and fracture
risk in patients with COPD is not comprehensively
addressed during chronic disease management and consul-
tations, despite being recognised as an important issue.
There are a number of important factors that are likely to
contribute to this including system-wide, educational,
awareness and also lack of clear guidance. Even for
Table 2 List of Suggested Investigations When Considering
Secondary Causes of Osteoporosis Besides COPD
Assess Other Potential Causes of Secondary Osteoporosis
The following investigations should be considered in order to identify
other causes of secondary osteoporosis where osteoporosis is
diagnosed:
● Full blood count
● Protein electrophoresis for multiple myeloma
● Renal function
● Liver function
● Glycosylated haemoglobin (HbA1c)
● Thyroid function
● Bone biochemistry (calcium, phosphate and alkaline phosphatase
and if abnormal, parathyroid hormone levels)
● Testosterone
● Vitamin D
Table 3 Management Options That Need to Be Considered for
Patients at Risk of Fragility Fractures
Management for “at risk” of fracture group is holistic and includes
recommendation of
● Engaging in discussion and informing the patient appropriately (via
conversation and leaflets)
● Smoking cessation interventions where appropriate. It may be an
additional encouragement for some to stop smoking
● Recommendation to increase activity (especially weight-bearing
exercise)
● Offering referral to pulmonary rehabilitation (if not attended in the
last year)
● Dietary optimisation
● Falls risk ± falls programme where applicable
● Frailty assessments ± optimisation where applicable
● Pharmacological elements:
○ Medicines review
○ Optimising inhaled corticosteroid dose
○ Reviewing and monitor oral corticosteroid rescue courses
○ Keeping any maintenance oral corticosteroids to a minimum
○ Bisphosphonates but bearing in mind
○ Adherence
○ Side effects – especially gastro-oesophageal reflux disease and
osteonecrosis.
○ Combined with oral calcium and vitamin D – adequate vitamin
D levels prior to initiating bisphosphonates reduce the risk of
secondary hyperparathyroidism and increases the effective-
ness of anti-resorptive medications
○ Given for a certain duration but then drug holiday usually
required
○ Specialist Review required prior to anabolics and intravenous
preparations
Table 4 Reasons for Referral to Metabolic Bone Disease Specialist
● Loss of BMD despite treatment
● According to locally approved guidelines
● Intolerant of standard therapy and therefore considering anabolic
or intravenous preparations. Blood bone turnover markers may be
helpful in monitoring bone health during a specialist review
Gupta et al Dovepress
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patients who have sustained a fragility fracture, studies
have shown that treatment initiation is inadequate.38–40
Further, for many patients, osteoporosis is asymptomatic
which means a pro-active approach is required to identify
who might be at risk.41 Certainly, for people with COPD,
there is currently no guidance on how to assess bone
health during a routine consultation but where it is system-
atically done, it can identify those at risk.6,15 However,
there are many other priorities at the annual assessment
such as review of exacerbation history, symptoms, assess-
ment of lung function, advising on smoking cessation and
inhaler technique. Developing a systematic approach to
assessing and addressing bone health across primary and
secondary care could improve identification of those who
are at risk of fractures and who requires treatment in
a timely manner and thereby reduce fractures. The big
question remains as to how this can be conducted and
not at the detriment of other elements of patient care.
Whilst elements of the fracture risk score can be com-
pleted through a semi-automated or a patient self-
completed questionnaire, clearly, the impact on discussing
results and the subsequent pathway needs time and spe-
cialist education.
Another important barrier to addressing bone health is
limited opportunity for learning and minimal guidance for
HCPs on practically assessing and treating osteoporosis in
patients with COPD. This is not unique to COPD.42,43
Whilst consensus statements such as this highlight this
knowledge gap in order to address and aim to improve
learning opportunities, clearly, this is some step from
implementing bone health assessment into routine clinical
care and that implementation step is imperative.44 National
Osteoporosis Guideline Group (NOGG) recommends
management of osteoporosis to be incorporated into the
training programmes of all relevant disciplines.41
Educational campaigns for HCPs, highlighting the burden
of disease, importance of fracture risk assessment tools
and cost–benefit of treatment could help raise awareness.
Signposting HCPs to websites and e-learning packages
with information on osteoporosis may also facilitate their
understanding and an outcome of this consensus is for the
committee to work with stakeholders.
Whilst the opinion of the consensus group was that
a systematic approach to bone health and fracture risk
should be provided to all patients with a current diagnosis
of COPD, the feasibility was questioned. In light of this,
a staged approach to implementation was discussed, start-
ing off with higher risk groups that can be determined from
GP computer records such as patients with previously
recorded fragility fracture,45 older age20,46 and those on
maintenance or frequent oral glucocorticoids.15,47 COPD-
specific characteristics relating to severity of disease, such
as airflow obstruction, are also associated with osteoporosis
and fracture risk and there is an argument that these patients
would also need priority for assessment.7,48 However, the
decision for assessment and/or treatment needs to be made
on an individual basis, as there may be patients in whom
fracture risk assessment or therapy might not be appropriate
(eg those receiving end of life care).
The roundtable group decision to assess fracture risk
within 6–12 months of a new diagnosis of COPD was
a pragmatic decision so as not to overburden the patients
following a COPD diagnosis. For patients with established
COPD, the annual review is considered the optimal oppor-
tunity to assess co-morbidities in general and reinforce
lifestyle modifications such as smoking cessation and
exercise rehabilitation, which are relevant for both COPD
and osteoporosis.22 Therefore, it is intuitive to address
bone health within this setting. Other points of care,
where periodical reviews of COPD related risk factors
and self-management strategies are carried out, can also
be useful in addressing bone health. Pulmonary rehabilita-
tion is an important setting, where the risk factors common
to fragility fractures are already assessed. It also offers an
opportunity to emphasise the benefits of strength training
and nutrition on not only COPD but also its associated co-
morbidities like osteoporosis.49
The pathway highlights the need for a fracture risk
assessment tool, which can quantify risk and aid in the
targeted use of DEXA scans. Fracture risk assessment
tools such as FRAX® and QFracture® are two validated
models that are recommended by national osteoporosis
guidelines.20,41 Both are straightforward to complete
although the QFracture® is more comprehensive, factoring
in history of falls and COPD within the fracture risk
calculations.50,51 Both tools have been shown to reason-
ably predict fracture risk in COPD in line with non-COPD
populations.15 The recommendation is to assess fracture
risk rather than relying solely on BMD to govern treatment
irrespective of which assessment tool is used. Where
a patient has an indeterminate risk or pharmacotherapy is
considered to be started, a DEXA bone scan to permit
monitoring is recommended.41
For those where osteoporosis is detected through
DEXA scanning or identification of a fragility fracture, it
is important to consider alternative secondary causes other
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than COPD. Certainly, vitamin D deficiency, secondary
hyperparathyroidism and hypogonadism are common in
COPD.32,48,52,53 Previous studies have advocated screen-
ing of secondary causes through medical history, physical
examination and biochemical tests.54,55 Hence, the con-
sensus includes recommendations of other investigations.
Former fragility fractures warrant consideration of “high
risk” in their own right: Vertebral and hip fractures are more
common in COPD than in the general population.15,56 As
well as increasing the risk of further fragility fractures, ver-
tebral fractures have also been shown to reduce lung function
even when asymptomatic.53 Diagnosis of a new vertebral
fracture would allow prompt initiation of secondary preven-
tion treatment, bypassing the pathway for risk assessment.
Whilst routine assessment for vertebral fractures is not
appropriate, it could be considered if there is a clinical suspi-
cion and certainly opportunistically looked for when imaging
for other reasons is available.
The consensus group did not diverge from standard phar-
macotherapy pathways for those requiring treatment. There
is an overwhelming amount of evidence demonstrating the
protective effect of bisphosphonates for those at risk or with
osteoporosis,57–59 although the evidence in COPD isminimal
with no studies studying fracture prevention and only one
small study demonstrating a modest improvement in BMD
for those on treatment.60 Recommendation for monitoring
GORD as a side effect of bisphosphonates was based on the
condition being common within COPD and associated with
an increased risk of exacerbations.61 Not only can this nega-
tively impact lung function and quality of life,62 but the use
of rescue courses of oral steroids during exacerbations may
further impair bone health. Repletion of vitamin D levels
prior to initiating bisphosphonates is also an important aspect
of the management. Vitamin D insufficiency in patients on
bisphosphonates appears to be associated with a poorer
response to the antiresorptive medication.63 This may be in
part due to vitamin D deficiency causing secondary hyper-
parathyroidism, which increases bone resorption, hence
counteracting the protective effects of antiresorptives.64
The consensus group also flagged important non-
pharmacological options, some COPD specific. The recom-
mendation for people at high or intermediate risk of fracture
to stop smoking was based on indirect evidence from
10 cohort studies (n = 59,232), suggesting that smoking
cessation may reduce the risk of osteoporotic fragility frac-
ture in women.65 Furthermore, a meta-analysis on smoking
and BMD showed that bone loss was greater in current
smokers than non-smokers by an additional 2% every 10
years increase in age.66 Similarly, exercise is shown to
reduce the risk of major osteoporotic fractures by reducing
the risk of falls and independently preserving bone density.
A Cochrane systematic review that assessed the evidence
from 159 randomised control trials (n = 79,193) on inter-
ventions for preventing falls in older people living in the
community reported that exercise reduces the rate of falls
and the risk of fracture.67 In a randomised control trial, lung
transplantation patients who underwent six months of exer-
cise significantly gained BMD, whilst the patients who were
not prescribed exercise (controls) lost BMD.68 Whilst such
non-pharmacological strategies should be advocated in all
patients with COPD regardless of fracture risk, the knowl-
edge that there is an increased risk of fractures may aid in
adherence to such lifestyle modifications.
In otherwise healthy individuals treated for osteoporo-
sis, repeat DEXA scan is usually recommended after
a minimum of two years of anti-resorptive treatment, as
it takes a minimum of two years to have a significant
change in BMD.20 Duration of anti-resorptive therapy is
usually between 3 and 5 years and is based on evidence
showing positive effects of therapy at reducing fracture
risk without increasing the prevalence of long-term side
effects.41 NOGG recommends continuation of treatment in
patients who obtain a fracture despite being on treatment
or in whom the bone mineral density T score remains less
than or equal to −2.5.41
The majority of the patients completing the survey had
a limited understanding of the impact of fracture risk and
osteoporosis in COPD. This is an important issue as
patients may not know they have the disease until
a fracture occurs. Engagement with primary prevention
through weight-bearing exercises, smoking cessation and
adequate nutritional intake would only be possible if
patients understand the implications of the disease in
COPD. Park et al demonstrated an improvement in osteo-
porosis self-efficacy, fall-self efficacy, and calcium and
vitamin D intake for community-dwelling elderly partici-
pants after an individualised educational intervention con-
sisting of brochures and formal exercise programmes.69
The consensus suggested developing a bone health leaflet,
which would particularly emphasise the importance of
lifestyle modifications in improving BMD and fracture
risk. Working with organisations such as BLF and Royal
Osteoporosis Society to co-ordinate educational events at
focus group meetings could help raise awareness in the
community.
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We acknowledge the limitations of our methodology.
Whilst the roundtable meeting was open to a variety of
multidisciplinary staff and several stakeholder invites
were prompted from the open free-text box on the sur-
vey, the process did not involve open applications and
selection. Further, there was an East Midlands predomi-
nance. Similarly, the majority of the respondents for the
HCP survey were also from the Midlands. Connotations
here may be that the views and suggestions made regard-
ing management of osteoporosis in COPD may not
reflect the clinical practice across the UK. Furthermore,
the recommendations made at the consensus meeting
were not graded according to the level of evidence that
form the basis of the suggestions. However, the lack of
evidence in many areas prompted the consensus as
opposed to formal guidelines at this stage.
Conclusion
Osteoporosis is a common and debilitating condition in
patients with COPD. Whilst the importance of fracture pre-
vention within these patients is accepted, this does not cur-
rently translate universally into clinical practice. Limited
knowledge of fracture assessment and lack of time to prior-
itise bone health during consultations are the main HCP
barriers to this. Development of a consensus document
incorporating the current literature on managing osteoporosis
in COPD and outlining important elements of a systematic
and holistic approach to addressing bone health for indivi-
duals with COPD is key to overcoming these barriers but
requires opportunities to disseminate the information, educa-
tional resources and time for it to be implemented. In tan-
dem, patient information on bone health is key.
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